Clough Capital Partners L P Decreases Stock Position in DexCom, Inc. $DXCM

Key Points

• Clough Capital Partners L P significantly reduced its holdings in DexCom, Inc. by 96.6%, owning only 5,670 shares worth $387,000 as of the latest quarter.
• Several institutional investors, including Golden State Wealth Management LLC and Private Trust Co. NA, have increased their positions in DexCom, reflecting strong interest from institutional investors.
• DexCom reported earnings per share of $0.48 for the latest quarter, surpassing analysts' expectations and marking a year-over-year revenue increase of 15.2%.

Clough Capital Partners L P decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 96.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,670 shares of the medical device company's stock after selling 160,180 shares during the period. Clough Capital Partners L P's holdings in DexCom were worth $387,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC raised its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in DexCom during the first quarter valued at about $27,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter worth about $38,000. Alpine Bank Wealth Management purchased a new position in shares of DexCom in the first quarter worth about $40,000. Finally, Private Trust Co. NA increased its holdings in shares of DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Up 2.9%

DexCom stock traded up $2.14 during trading hours on Wednesday, hitting $76.44. 1,682,675 shares of the stock traded hands, compared to its average volume of 3,900,037. The firm's 50-day moving average price is $81.90 and its two-hundred day moving average price is $79.28. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market cap of $29.98 billion, a PE ratio of 53.00, a PEG ratio of 1.58 and a beta of 1.48. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business's revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $88.99, for a total transaction of $130,459.34. Following the sale, the executive vice president directly owned 106,689 shares of the company's stock, valued at approximately $9,494,254.11. The trade was a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,722 shares of company stock valued at $1,306,131. Insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. The Goldman Sachs Group initiated coverage on DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Oppenheimer lifted their price objective on DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, July 31st. Citigroup reiterated a "buy" rating and issued a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. UBS Group lifted their price objective on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Finally, Truist Financial initiated coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.